This phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with gemcitabine hydrochloride and to see how well they work in treating younger patients with Hodgkin lymphoma that has returned or does not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may find cancer cells and help kill them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin together with gemcitabine hydrochloride may kill more cancer cells.
Clinical Trial Information
Trial Contact: Boettger, Sadie; El-Shami, Jessica; O'Neill, Melissa
Age Group: Pediatric
Phase: Drug: Phase I
Principal Investigator: Vincent F. Giusti, MD
Secondary Protocol No: AHOD1221
Applicable Disease Sites: Relapsed or Refractory Hodgkin Lymphoma